Background and Purpose-Microalbuminuria, a marker of both kidney disease and endothelial dysfunction, may be associated with global vascular risk, but the nature and magnitude of the link between microalbuminuria and incident stroke has not been clearly defined. The purpose of this study was to assess the consistency and strength of the association of microalbuminuria with risk of stroke in prospective studies using meta-analysis. Methods-We conducted a systematic search of electronic databases and bibliographies for studies reporting a multivariate-adjusted estimate, represented as relative risk with 95% CI, of the association between microalbuminuria and stroke risk. Studies were excluded if a majority of study participants had established kidney disease or pre-eclampsia. Estimates were combined using a random-effect model. Results-We identified 12 studies, with a total of 48 596 participants and 1263 stroke events. Overall, presence of microalbuminuria was associated with greater stroke risk (relative risk, 1.92; 95% CI, 1.61 to 2.28; PϽ0.001) after adjustment for established cardiovascular risk factors. There was evidence of significant heterogeneity in the magnitude of the association across studies (P for heterogeneity Ͻ0.001, I
O ver the last 4 decades, several prospective clinical studies have identified a series of independent risk factors for symptomatic vascular events, including stroke. 1, 2 However, a better understanding of the multifactorial pathogenesis of atherosclerosis, the underlying entity behind most vascular events, and the fact that many of these events occur in persons who do not harbor conventional vascular risk factors has prompted a search for novel risk factors for prediction of cardiovascular disease. 3 Nonetheless, the clinical value of many of these emerging risk factors remains uncertain largely due to inconsistency of data, paucity of prospective studies, or lack of evidence that their predictive ability is independent of conventional risk factors. 3 One such emerging vascular risk factor is microalbuminuria. 4 Microalbuminuria is generally defined as a urinary albumin excretion rate (or albumin excretion rate) of 30 to 299 mg/day or an albumin:creatinine ratio of 2.5 to 25 mg/mmol in men and 3.5 to 25 mg/mmol in women. 4 Although often seen as a sign of early kidney disease (ie, impairment in glomerular filtration barrier), microalbuminuria interacts with several conventional vascular risk factors and is an independent marker of endothelial dysfunction. 4 Indeed, it is thought that assessing kidney structure using this relatively simple test could be a window to the systemic vasculature, that is, leaky renal vessels reflecting the permeability of the vasculature in general and an individual's susceptibility to target organ damage. 5 There is convincing evidence of an independent positive relationship between overt proteinuria and stroke risk, 6 but the nature and magnitude of the link between microalbuminuria and incident stroke has so far not been systematically investigated. In this study, we aimed to assess the consistency and strength of the association of microalbuminuria with risk of stroke in prospective cohort studies using meta-analysis.
"proteinuria" or "albuminuria" or "microalbuminuria" or "macroalbuminuria" crossed with "stroke" or "cerebrovascular disease" or "cerebrovascular attack" or "cerebral ischemia" or "brain ischemia" or "intracranial hemorrhage." We restricted the search to human studies. There were no language restrictions. Manual searches of bibliographies of all relevant studies and review articles were reviewed and identified by 2 investigators (M.L. and K.H.C.).
Study Selection and Data Abstraction
Studies were selected if they met the following entry criteria: (1) prospectively collected data obtained within cohort studies or clinical trials; (2) reported quantitative estimates of the multivariate-adjusted relative risk (RR) and 95% CI for stroke associated with microalbuminuria; and (3) follow-up duration was at least 1 year. Studies were excluded if (1) the study design was cross-sectional, case-control, or retrospective cohort studies; (2) the majority of the participants had chronic kidney disease (ie, estimated glomerular filtration rate Ͻ60 mL/min/1.73 m 2 , kidney transplant, Fabry disease, eclampsia, or preeclampsia; (3) only reported unadjusted or age-and sex-adjusted RR; and (4) did not report 95% CI. The prespecified definitions of microalbuminuria are listed in Table 1 . 8 Studies that used slightly varying definitions were included if they were otherwise comparable. All data from eligible studies were abstracted independently by 2 investigators (M.L. and K.H.C.). Discrepancies were resolved by discussion with a third investigator (B.O.) and by referencing the original report.
Assessment of Study Quality
We assessed quality of all articles that met the selection criteria with the following 8 characteristics: (1) prospective study design; (2) maintenance of comparable groups; (3) adjustment of potential confounders; (4) documented loss of follow-up rate; (5) outcome assessed blind to exposure status; (6) clear and proper definition of exposures (microalbuminuria) and outcomes (stroke); (7) temporality (microalbuminuria measured at baseline, not at time of outcomes assessment) and (8) follow-up of at least 1 year. Studies were graded as good quality if they met 6 to 8 criteria; fair if they met 3 to 5; and poor if they met Ͻ3 criteria.
Statistical Analysis
Data analysis used multivariate-adjusted outcome data (expressed as RRs and 95% CIs). We converted these values in every study by using their natural logarithms, and the SEs were calculated from these logarithmic numbers and their corresponding 95% CIs. The statistical analysis used the inverse variance approach to combine log RRs and SEs. We used a random-effect model and explored for sources of inconsistency (I 2 ) and heterogeneity. A fixed-effect model was also conducted for the comparison to the random-effects model on the overall risk estimate. The Cochrane Collaboration's Review Manager Software Package (RevMan 5) was used for the meta-analysis. All reported probability values were 2-sided with significance set Ͻ0.05. Heterogeneity was assessed by probability value of 2 statistics and I 2 , which describes the percentage of variability in the effect estimates that is due to heterogeneity rather than chance. 9, 10 We regarded I 2 of Ͻ40% as "heterogeneity might not be important" and Ͼ75% as "considerable heterogeneity" based on the suggestion of Cochrane Handbook for Systemic Review of Interventions. 11 All available data were included in the primary analysis. Subsequent subgroup analyses were conducted according to population (general versus diabetes versus stroke history), ethnicity (whites versus Asians and American Indians), microalbuminuria prevalence at entry (Ͻ30% versus Ն30%), measurement methods of microalbuminuria (spot urine albumin concentration [UAC] versus urine albumin creatinine ratio [UACR]), follow-up duration (Ͻ7 years versus Ն7 years), participant number (Ͻ2000 versus Ն2000), end point (fatal stroke versus fatalϩnonfatal stroke), stroke subtypes (ischemic versus hemorrhagic versus nonspecific type), study type (observational cohorts versus secondary analysis of clinical trials), microalbuminuria versus stroke assessed as a primary study objectives compared with secondary objectives, and whether definitions of microalbuminuria found in each study completely versus partially corresponded to our prespecified microalbuminuria definition.
Finally, we also did a sensitivity analysis to further explore the robustness of our results. To identify any study that may have exerted a disproportionate influence on the summary treatment effect, we removed each individual trial from the meta-analysis 1 at a time. A funnel plot based on the primary outcome was conducted to evaluate potential systematic bias in studies, including publication bias.
Results
The literature review identified 160 full articles for detailed assessment, among which 124 were excluded for no stroke estimate, 6 for no adjusted estimate or only age-and sexadjusted estimate, and 18 for only proteinuria and stroke risk estimate. Our final primary analysis included 12 prospective cohort studies 12-23 with 13 estimates because 1 study reported diabetes mellitus (DM) and non-DM population separately ( Figure 1 ). 16 The study characteristics are shown in Table 2 . There were a total 48 596 participants and 1263 stroke events in the current meta-analysis. Among 13 estimates, 6 derived from the general population, [15] [16] [17] [18] 22, 23 5 from a Type 2 DM population, 13, 14, 16, 19, 20 and 2 from a population with a stroke history. 12, 21 Nine studies were from a white-dominant population, [12] [13] [14] [15] [16] [17] [18] [19] 22 2 from an Asian population, 20,21 and 1 from an American Indian population. 23 The participant number ranged from 370 21 to 23 433. 22 The follow-up duration ranged from 1.1 years 21 to 13.4 years. 23 Three of the 12 studies used UAC 12, 16, 19 for microalbuminuria measurement, whereas 9 used UACR. 13-15,17,18,20 -23 Eleven studies reported fatal plus nonfatal stroke as a primary end point, whereas 1 reported fatal stroke as a primary end point. 19 Three studies used ischemic stroke as a primary end point 15, 18, 20 and others used all reported stroke as a primary end point. [12] [13] [14] 16, 17, 19, [21] [22] [23] Overall quality of studies was good (median, 6; range, 5 to 7).
Overall, presence of microalbuminuria was associated with greater subsequent stroke risk (RR, 1.92; 95% CI 1.61 to 2.28; PϽ0.001) after adjustment for established cardiovascular risk factors (Figure 2 ). There was evidence of significant heterogeneity in the magnitude of the association across studies (P for heterogeneity Ͻ0.001, I
2 ϭ68%). The exclusion of any single study from the analysis did not alter the overall finding in a sensitivity test (data not shown). There was mild asymmetrical appearance lacking studies on the left lower part of the funnel plot ( Figure 3) . The RR from a fixed-effect model was 1.82 (95% CI, 1.65 to 1.99; PϽ0.001). Table 3 shows microalbuminuria was associated with increased risk of subsequent stroke in all subgroups when we stratified the estimates by population, study type, ethnicity, microalbuminuria prevalence at entry, follow-up duration, participant number, measurement methods of microalbuminuria, and end point. Significant heterogeneity was found between the DM population and the population with a stroke 
Discussion
In this meta-analysis of 12 prospective cohort studies, among almost 49 000 individuals experiencing Ͼ1200 stroke events, we found that persons with baseline microalbuminuria have a risk of future stroke that is approximately 90% greater than those without microalbuminuria. This relationship was consistent across diverse population subgroups (ie, general populations, diabetic populations, and populations with a stroke history). Furthermore, the size and inclusion of only prospective data strengthen the robustness of our findings, because issues of selection bias, recall bias, and reverse causality are unlikely. In addition, all studies included in our meta-analysis reported a multivariate-adjusted RR, which probably mitigated the possibility of known confounding influencing our results.
We observed that the impact of microalbuminuria was greatest in the population with a history of stroke and relatively modest in the diabetic population. It is conceivable that this distinction is because among the diabetics, microalbuminuria may have more likely been a reflection of "earlier stage" nephropathy and not necessarily widespread vascular disease that could have precipitated future strokes. On the other hand, microalbuminuria among those with prior cerebrovascular bed damage (stroke) may have signified persons with extensive interaction of vascular factors 24, 25 and vascular instability at highest risk for further cerebrovascular events. 4 We found microalbuminuria had the greatest impact on ischemic stroke, which would be expected given the aforementioned postulated underlying mechanisms for this association, followed by unspecified stroke type, and then an almost neutral effect on hemorrhagic stroke, further underscoring the likelihood that atherosclerosis might be the pathological link between microalbuminuria and stroke.
Our meta-analysis, based on observational studies, cannot prove causality and mechanistically it is unclear how albuminuria would directly cause stroke. However, there was some evidence implying that stroke risk might be reduced when we reduced microalbuminuria. A study showed that short-term reduction in albuminuria after initiation of blood pressurelowering treatment has been associated with lower long-term stroke risk. 26 Among various blood pressure-lowering agents, for a similar level of attained blood pressure, modulators of the renin-angiotensin system lower urine albumin excretion or decrease incidence of new-onset microalbuminuria more effectively than other agents among patients with diabetes. 27, 28 In fact, among microalbuminuric subjects, treatment with fosinopril had a significant effect on lessening urinary albumin excretion and was associated with a trend in reducing cardiovascular events, results that could not completely be attributed to the reduction in arterial blood pressure. 29, 30 Future studies are needed to investigate whether limiting urinary albumin excretion with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers may reduce cardiovascular events, including strokes, beyond their blood pressure-lowering effects.
Compared with studies whose definitions completely corresponded to our prespecified microalbuminuria definition, those that only partially did so appeared to have a stronger link to stroke risk. Most of the studies in the latter category did not set an upper limit of UACR, which means participants with macroalbuminuria were also included. As such, it is not surprising that stroke risk was higher with data likely comprising the entire albuminuria range (microalbuminuriaϩmacroalbuminuria). CVD indicates cardiovascular disease; ACEI, angiotensin-converting enzyme inhibitor; NR, not reported; BMI, body mass index; BP, blood pressure; AF, atrial fibrillation; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; HDL, high-density lipoprotein; TG, triglycerides; HF, heart failure; CHD, coronary heart disease; MI, myocardial infarction; eGFR, estimated glomerular filtration rate; LDL, low-density lipoprotein.
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The current systematic review found the prevalence of microalbuminuria ranged from 12% 22 to 40%. 13 The high prevalence rate of microalbuminuria raises a question whether it is cost-effective to screen microalbuminuria in diabetic and general populations. Health economic analyses have shown that screening for albuminuria in the Type 2 diabetic patients and subsequent initiation of angiotensin II antagonists treatment in those found positive contributed to better outcomes, including reduction of cardiovascular event, and may represent an excellent value. 31, 32 On the other hand, some have argued that simply treating all middle-aged diabetic patients with angiotensinconverting enzyme inhibitors is a simple strategy that provides additional benefit at modest additional cost. 33 For the general population, a strategy of annual dipstick screening for gross proteinuria with follow-up testing and treatment with an angiotensin-converting enzyme inhibitor may not be cost-effective with regard to slowing progression of kidney disease or decreasing mortality. 34 This is because the yield is so low due to the low prevalence (Ͻ1%) of gross proteinuria in the general population. 35 However, screening for the general population for microalbuminuria and subsequently treating those found positive with fosinopril may be more cost-effective compared with no screening and adopting an ordinary healthcare perspective given the substantially higher rates of microalbuminuria in the general population. 36 Some limitations need to be mentioned. First, meta-analyses can be constrained by comprehensiveness of searches, methodological rigor of the included studies, and publication bias, especially when the meta-analysis was conducted of epidemiological studies rather than randomized controlled trials. Second, the studies varied with respect to the characteristics of participants, definition of stroke in outcome assessment, follow-up duration, among others and indeed, heterogeneity was found by formal analysis. Still, our sensitivity analysis showed that removing any 1 study did not alter the main meta-analysis findings. Finally, there was evidence of a publication bias as seen in the funnel plot (Figure 3 ). Some studies did not report RR with 95% CI when an insignificant result was found after adjusting for known cardiovascular risk factors 37 and, as such, could not be included in our meta-analysis. This issue probably resulted in an overestimation of the association between microalbuminuria and stroke risk. However, when we exclude 3 estimates with larger SEs, the overall RR between microalbuminuria and stroke risk decreased to 1.61 (95% CI, 1.39 to 1.85).
In conclusion, our formal meta-analysis found a significant and strong association between microalbuminuria and subsequent stroke risk across various population subtypes after adjustment of established cardiovascular risk factors. Future studies, preferably randomized controlled studies of agents that lower or prevent microalbuminuria, should explore whether microalbuminuria is just a risk marker or a potentially modifiable risk factor for stroke.
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